Last $133.92 USD
Change Today +2.46 / 1.87%
Volume 5.1M
As of 8:04 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/17/14 - $134.41
52 Week Low
06/24/13 - $81.33
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Related Businessweek News

View More BusinessWeek News

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. The company has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,400 Employees
Last Reported Date: 02/25/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
Total Annual Compensation: $651.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $641.5K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Allergan Inc. Proposes Amended and Restated Certificate of Incorporation

Allergan Inc. announced AGM to be held on May 06, 2014, to approve the proposal of amendment and restatement of amended and restated certificate of incorporation to provide stockholders with the right to act by written consent.

Consumers Files Proposed Class-Action Lawsuit Against Allergan Inc. and SkinMedica

Consumers filed a proposed class-action lawsuit against Allergan Inc. and its subsidiary, SkinMedica, claiming that the companies have misbranded and unlawfully marketed Tissue Nutrient Solution (TNS), a skin-care product line containing human growth factors obtained from human foreskin tissue which could increase the risk of cancer and pose other health risks. The lawsuit, filed by consumer-rights law firm Hagens Berman in the U.S. District Court for the Central District of California, claims that for at least the past four years, SkinMedica has failed to disclose significant safety concerns associated with TNS products while marketing the products without appropriate government approval, proper labeling, or adequate safety studies. The suit alleges that in marketing their TNS products, Allergan and its subsidiary SkinMedica did not adequately disclose the health risks associated with these growth factors. The lawsuit is a proposed class action based upon California's consumer protection laws, and seeks to represent a class of all persons in the U.S. who purchased SkinMedica's TNS products during the last four years.

Allergan Inc. Appoints Ali Moghaddam to its Board of Advisors

Vansen Pharma Inc. announced the appointment of Mr. Ali Moghaddam to its Board of Advisors. Mr. Moghaddam is an accomplished pharmaceutical executive with over 25 years of experience in both Canada and the U.S., having played a transformational role with companies such as Bristol- Myers Squibb Canada, Linson Pharma Inc. (generic business unit of BMS), Allergan Canada, and E-Z-EM Inc. U.S. (now part of Bracco Group). He brings a proven track record of hands-on leadership within the life sciences field, in the areas of Product Life Cycle Management, Sales, Business Development, Marketing, and Finance. Mr. Moghaddam is currently the Vice President of Sales (Canada) for Actavis Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $133.92 USD +2.46

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $197.39 USD -1.99
Mylan Inc/PA $46.92 USD -0.29
Regeneron Pharmaceuticals Inc $296.74 USD -3.40
Shire PLC 2,925 GBp +25.00
Valeant Pharmaceuticals International Inc C$134.45 CAD +0.80
View Industry Companies

Industry Analysis


Industry Average

Valuation AGN Industry Range
Price/Earnings 31.9x
Price/Sales 6.3x
Price/Book 6.2x
Price/Cash Flow 36.4x
TEV/Sales 5.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at